India, June 14 -- Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; and Alumis, which is advancing its lead therapy toward a potentially pivotal trial in lupus expected to commence next quarter.
Read on.
TXMD Weighing Strategic Alternatives
TherapeuticsMD Inc. (TXMD), a company that owns rights to pharmaceutical royalties, was one of the top gainers on Friday - with shares soaring over 20%.
The company continues to evaluate a range of strategic alternatives, such as acquisitions, mergers, asset sales, business combinations, and other potential transactions.
In th...